SEC Form 3 
FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 	  
OMB APPROVAL
OMB Number:	3235-0104	
Estimated average burden	
hours per response:	0.5	

	
1. Name and Address of Reporting Person*
GILL SIMBA	

(Last)	(First)	(Middle)	
620 MEMORIAL DRIVE, SUITE 200	

(Street) 
CAMBRIDGE	MA	02139	

(City)	(State)	(Zip)	
	2. Date of Event Requiring Statement (Month/Day/Year)
05/08/2018 	3. Issuer Name and Ticker or Trading Symbol 
Evelo Biosciences, Inc. [ EVLO ] 		
		4. Relationship of Reporting Person(s) to Issuer 
(Check all applicable) 
X	Director		10% Owner	
X	Officer (give title below)		Other (specify below)	
President & CEO	
	5. If Amendment, Date of Original Filed (Month/Day/Year)				
			6. Individual or Joint/Group Filing (Check Applicable Line) 
X	Form filed by One Reporting Person	
	Form filed by More than One Reporting Person	
	
Table I - Non-Derivative Securities Beneficially Owned	
1. Title of Security (Instr. 4) 	2. Amount of Securities Beneficially Owned (Instr. 4) 	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 	4. Nature of Indirect Beneficial Ownership (Instr. 5) 	
Common Stock	38,612	D		
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities) 	
1. Title of Derivative Security (Instr. 4) 	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 	4. Conversion or Exercise Price of Derivative Security 	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 	6. Nature of Indirect Beneficial Ownership (Instr. 5) 	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	(1) 	11/04/2025	Common Stock	245,853	0.49	D		
Stock Option	(2) 	10/06/2026	Common Stock	596,960	1.14	D		
Stock Option	(3) 	12/14/2027	Common Stock	183,868	3.96	D		
Stock Option	(4) 	04/03/2028	Common Stock	134,836	10.48	D		
Stock Option	(5) 	04/03/2028	Common Stock	144,643	10.48	D		
Explanation of Responses:	
1. The option is currently exercisable.	
2. The option vested as to 25% of the total grant on July 1, 2017 and has vested or will vest in equal quarterly installments over a three year period thereafter.	
3. The option vests and becomes exercisable as to 25% of the total grant on July 1, 2018 and vests in equal quarterly installments over a three year period thereafter.	
4. The option vests and becomes exercisable as to 25% of the total grant on March 21, 2019 and vests in equal quarterly installments over a three year period thereafter.	
5. The option vests and becomes exercisable as to 50% of the total grant on March 21, 2022 and as to the remaining 50% on March 21, 2023.	
Remarks:	
Exhibit 24 - Power of Attorney.	
	/s/ Jonathan Poole, Attorney-in-Fact for Balkrishan (Simba) Gill, Ph.D.	05/08/2018	
	** Signature of Reporting Person	Date	
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).	
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.	
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.	
                                   POWER OF ATTORNEY

        With respect to holdings of and transactions in securities issued by
Evelo Biosciences, Inc. (the "Company"), the undersigned hereby constitutes and
appoints the individuals named on Schedule A attached hereto and as may be
amended from time to time, or any of them signing singly, with full power of
substitution and resubstitution, to act as the undersigned's true and lawful
attorney-in-fact to:

        1.      prepare, execute in the undersigned's name and on the
        undersigned's behalf, and submit to the United States Securities and
        Exchange Commission (the "SEC") a Form ID, including amendments thereto,
        and any other documents necessary or appropriate to obtain and/or
        regenerate codes and passwords enabling the undersigned to make
        electronic filings with the SEC of reports required by Section 16(a) of
        the Securities Exchange Act of 1934, as amended, or any rule or
        regulation of the SEC;

        2.      execute for and on behalf of the undersigned, Forms 3, 4, and 5
        in accordance with Section 16 of the Securities Exchange Act of 1934,
        as amended, and the rules thereunder;

        3.      do and perform any and all acts for and on behalf of the
        undersigned which may be necessary or desirable to complete and execute
        any such Form 3, 4, or 5, complete and execute any amendment or
        amendments thereto, and timely file such form with the SEC and any stock
        exchange or similar authority; and

        4.      take any other action of any type whatsoever in connection with
        the foregoing which, in the opinion of such attorney-in-fact, may be of
        benefit to, in the best interest of, or legally required by, the
        undersigned, it being understood that the documents executed by such
        attorney-in-fact on behalf of the undersigned pursuant to this Power of
        Attorney shall be in such form and shall contain such terms and
        conditions as such attorney-in-fact may approve in such attorney-in-
        fact's discretion.

        The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution and resubstitution or revocation, hereby ratifying and confirming
all that such attorney-in-fact, or such attorneys-in-fact substitute or
substitutes, shall lawfully do or cause to be done by virtue of this Power of
Attorney and the rights and powers herein granted.

        The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934, as amended.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by Evelo
Biosciences, Inc., unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 8th day of May, 2018.

Signature:      /s/ Balkrishan (Simba) Gill, Ph.D
                ---------------------------------------
Print Name:     Balkrishan (Simba) Gill, Ph.D.

                                      Schedule A

        Individuals Appointed as Attorney-in-Fact with Full Power of
Substitution and Resubstitution

Jennifer Glennon
Jonathan Poole